“I didn’t have any of the typical symptoms like blood in my poo, so the diagnosis came as a massive shock,” said Zara. Zara ...

The Joint Subregional Cooperation Strategy that will provide a coordinated framework for technical cooperation to address common public health challenges in the Caribbean was signed today by the ...

At-home remedies like applying cold packs shortly after an injury can help reduce inflammation; while heat through warm ...

WITH the holidays upon us, it can be a challenging time for parents to juggle the stresses of work and childcare while trying ...

These interviews are the top episodes, by listens, from among the 21 podcast episodes The American Journal of Managed Care® ...

"Likely acts through multiple pathways." Groundbreaking study reveals overlooked factor behind increased cancer risk in women: 'Their cumulative public health impact is substantial' first appeared on ...

The use of cadonilimab in first-line treatment for advanced, recurrent, or metastatic cervical cancer was approved by the NMPA in May 2025.

Know why strong patient-practitioner communication is crucial in hypermobility management. Learn how bridging this gap can lead to better understanding, more accurate diagnoses, and personalized care.

Akeso's PD-1/CTLA-4 Bispecific Antibody Cadonilimab Approved for First-Line Treatment of Cervical Cancer in All-Comer Populations--Third Approved Indication for Cadonilimab ...

Akeso's PD-1/CTLA-4 Bispecific Antibody Cadonilimab Approved for First-Line Treatment of Cervical Cancer in All-Comer Populations—Third Approved Indication for Cadonilimab ...

HONG KONG, June 4, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the National Medical Products Administration (NMPA) has approved the company's ...